AOWM
ADMS

Alpha Omega Wealth Management’s Adamas Pharmaceuticals ADMS Stock Holding History

Alpha Omega Wealth Management’s Portfolio ADMS Stock Details ADMS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-250
Closed -$8K – 507
2017
Q4 		$8K Buy
+250
New +$6.98K ﹤0.01% 359

Other funds holding ADMS

State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
BWCA
Brenner West Capital Advisors New York $804M AUM 16.19% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Alpha Omega Wealth Management's ADMS Position: Q1 2018 in Review

Alpha Omega Wealth Management sold out of Adamas Pharmaceuticals (ADMS) in Q1 2018, closing a stake of 250 shares — an estimated $8K sold.

Alpha Omega Wealth Management first reported a position in ADMS in Q4 2017 and held it in 1 quarter. The position peaked at $8K in Q4 2017. 118 funds tracked by Wall St. Rank hold ADMS as of Q1 2018.

  • Alpha Omega Wealth Management reported no remaining Adamas Pharmaceuticals position as of Q1 2018 after selling out during the quarter.
  • Alpha Omega Wealth Management sold 250 Adamas Pharmaceuticals shares in Q1 2018, an estimated $8K.
  • Alpha Omega Wealth Management first reported a position in Adamas Pharmaceuticals in Q4 2017 and held it in 1 quarter.
  • Alpha Omega Wealth Management's Adamas Pharmaceuticals position peaked at $8K in Q4 2017.
  • 118 funds tracked by Wall St. Rank held Adamas Pharmaceuticals as of Q1 2018.

Based on Alpha Omega Wealth Management's 13F filing for Q1 2018, filed 1 May 2018.